Dialog Box


Associate Professor Nick Gottardo receives Collaborative Researcher of the Year Award

 A/Prof Nick Gottardo

The brilliant researcher received the Collaborative Researcher of the Year Award at an international research conference in Sydney on Saturday.

Based at Perth’s Telethon Kids Institute and funded by Cure Brain Cancer Foundation, A/Prof Gottardo is investigating the effectiveness of novel drugs in models of medulloblastoma, a common childhood brain cancer. On this project alone he collaborates with 20 researchers at seven institutes, hospitals and organisations around the world. 

A/Prof Gottardo’s pioneering work and collaborations have led to the development of an international clinical trial for medulloblastoma called SJ-ELiOT, which, when open, will recruit patients in Australia, the USA and Germany.

Affectionately known as ‘Saint Nick’ by his patients and their families, he was awarded this accolade at the annual DIPG Symposium, this year taking place in Sydney for the first time. The recipient of this prestigious award is decided by a panel, comprised of members of the DIPG Collaborative – an international body of 29 leading brain cancer organisations. 

Cure Brain Cancer Foundation CEO, Associate Professor Kerrie McDonald, herself a passionate advocate for collaboration in brain cancer research, says, “Tragically, brain cancer kills more Australian children than any other disease, and only by working together will we change that. The need for collaboration across all aspects of brain cancer research are obvious to me. It fosters transparency, shares resources, thus boosting efficiency and allows the cross-fertilisation of diverse ideas and approaches to similar issues. I’d like to send my personal congratulations to A/Prof Gottardo on this worthy accolade.”

Driven by a belief that it is unacceptable for children to die from brain cancer, A/Prof Gottardo has devoted his professional life to finding a cure for children’s cancer and says, “My goal is to cure as many children as possible, but with the best quality of life, so that they lead happy, productive, and dignified lives in the future.”

The Australian arm of his SJ-ELiOT clinical trial will be funded under the Australian Brain Cancer Mission (ABCM) – a $124 million Government-backed plan to double brain cancer survival in ten years and improve patients’ quality of life. Cure Brain Cancer Foundation spearheaded the establishment of the ABCM and since October 2017 has invested $4.3 million to ABCM projects,  including 13 research projects, four of which are clinical trials. 

Help us fund ground-breaking research